DDInter737 DDInter131
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
Fingolimod {u} (Compound) binds {v} (Gene) S1PR4
Fingolimod {u} (Compound) is included by {v} (Pharmacologic Class) Sphingosine 1-Phosphate Receptor Modulators
Fingolimod {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olanzapine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Fingolimod (Compound) treats multiple sclerosis (Disease)
Fingolimod (Compound) binds S1PR4 (Gene)
Fingolimod (Compound) is included by Sphingosine 1-Phosphate Receptor Modulators (Pharmacologic Class)
Fingolimod (Compound) causes Cardiac arrest (Side Effect)
Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine
Fingolimod may lead to a major life threatening interaction when taken with Tizanidine
Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib